Publicaciones (21) Publicaciones de JOSÉ LUIS REVUELTA HERRERO

2023

  1. Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 2855-2882

  2. Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy

    Frontiers in Oncology, Vol. 13

  3. Patient-reported outcome measures in severe asthma: an expert consensus

    Journal of Asthma

2022

  1. A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application

    Frontiers in Oncology, Vol. 12

  2. A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital

    Frontiers in Public Health, Vol. 10

  3. Implantación de una metodología para evaluar patient‑reported outcomes en pacientes con cáncer de pulmón: Protocolo del estudio PeOpLe (Patient‑reported Outcomes in Lung cancer )

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 46, Núm. 4, pp. 265-269

  4. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients

    Expert Opinion on Drug Safety, Vol. 21, Núm. 1, pp. 107-119

  5. Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients

    Journal of Oncology Pharmacy Practice, Vol. 28, Núm. 5, pp. 1259-1263

  6. Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App

    Frontiers in Oncology, Vol. 12

2021

  1. Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice

    Supportive Care in Cancer, Vol. 29, Núm. 8, pp. 4673-4681

  2. Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective

    Frontiers in Oncology, Vol. 11

  3. Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain

    Expert Review of Clinical Pharmacology, Vol. 14, Núm. 2, pp. 249-260

  4. Dpyd exome, mrna expression and uracil levels in early severe toxicity to fluoropyrimidines: An extreme phenotype approach

    Journal of Personalized Medicine, Vol. 11, Núm. 8

  5. Tocilizumab as salvage treatment of refractory pulmonary acute graft-versus-host disease

    Journal of Oncology Pharmacy Practice, Vol. 27, Núm. 3, pp. 751-755

2020

  1. Risks and medication errors analysis to evaluate the impact of a chemotherapy compounding workflow management system on cancer patients’ safety

    Health Informatics Journal, Vol. 26, Núm. 3, pp. 1995-2010

2019

  1. Drug safety surveillance within a strategy for the management of non-chemotherapy drug-induced neutropenia

    International Journal of Clinical Pharmacy, Vol. 41, Núm. 5, pp. 1143-1147

  2. Los medicamentos del futuro ya son una realidad: linfocitos T car

    Panorama actual del medicamento, Vol. 43, Núm. 423, pp. 469-476

  3. Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice

    Expert Opinion on Drug Safety, Vol. 18, Núm. 9, pp. 861-868

2018

  1. Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice

    Journal of Clinical Pharmacy and Therapeutics, Vol. 43, Núm. 6, pp. 906-909

  2. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients

    Annals of Pharmacotherapy, Vol. 52, Núm. 1, pp. 11-18